Australia to Lose Long-Acting Opioid Dependence Treatment as Sublocade Leaves the Market

Australians receiving treatment for opioid dependence are facing a significant change after pharmaceutical manufacturer Indivior announced it will discontinue the sale and marketing of Sublocade in Australia by December 31. The decision has raised concerns among addiction specialists, pharmacists, and healthcare providers who say the medication has transformed treatment for many patients living with opioid dependence.

Although an alternative long-acting injectable medication remains available, many clinicians warn that losing Sublocade could negatively affect patient outcomes, particularly for those who have achieved long-term stability using the medication.

A Commercial Decision With Real-World Consequences

Indivior, the U.S.-based pharmaceutical company behind Sublocade, confirmed that the product will no longer be supplied in Australia after the end of the year. Company representatives described the move as a commercial business decision rather than one based on safety or effectiveness.

The announcement follows another recent withdrawal from the Australian pharmaceutical market, with AstraZeneca also discontinuing the supply of its breast cancer and endometriosis treatment Zoladex, citing similar commercial reasons.

The Australian government acknowledged that decisions like these can create uncertainty for both patients and healthcare professionals but emphasized that medicine manufacturers ultimately control whether they continue supplying products to individual countries.

Officials stated that while maintaining access to safe, effective, and affordable medicines remains a national priority, governments cannot require private pharmaceutical companies to continue marketing medications that are no longer considered commercially viable.

Why Sublocade Became an Important Treatment Option

Sublocade was added to Australia's Pharmaceutical Benefits Scheme (PBS) in 2020 and quickly became an important treatment option for individuals managing opioid dependence.

Unlike traditional medications such as methadone or daily buprenorphine tablets, Sublocade is administered as a once-monthly injection by a healthcare professional. This significantly reduces the need for frequent pharmacy visits and provides consistent medication levels throughout the month.

For many patients, the treatment simplified recovery by allowing them to focus on work, family, education, and rebuilding their lives instead of scheduling daily medication appointments.

Healthcare providers also noted that the long-acting formulation reduced missed doses and improved treatment adherence, making it an important option for patients seeking greater stability.

Doctors Say Some Patients Respond Better

Although Buvidal, another long-acting injectable form of buprenorphine, will remain available through the PBS, clinicians caution that the two medications are not interchangeable for every patient.

Melbourne general practitioner Dr. Owen Harris explained that, in clinical practice, many patients experience better symptom control with Sublocade.

According to Harris, some individuals report feeling more stable throughout the dosing period, with fewer fluctuations in withdrawal symptoms or cravings. Others are able to extend the interval between injections beyond four weeks while maintaining effective treatment.

For these patients, switching medications may not produce the same results.

Many addiction specialists say that maintaining access to multiple treatment options is essential because recovery is highly individualized, and no single medication works equally well for everyone.

Global Pricing Pressures Affect Local Access

The withdrawal comes amid broader changes in the global pharmaceutical market.

Australian Health Minister Mark Butler recently noted that international drug pricing has become increasingly uncertain, particularly following policy discussions in the United States aimed at lowering prescription drug costs.

One proposal, commonly referred to as a "most favored nations" pricing model, seeks to align U.S. medication prices with those paid by other countries.

Industry experts say these changes have forced pharmaceutical manufacturers to reassess pricing strategies around the world.

Some analysts believe companies may decide to withdraw products from smaller markets rather than accept lower prices that could influence pricing negotiations in larger countries.

Former Medicines Australia chief executive Brendan Shaw said pharmaceutical companies are now evaluating global pricing decisions much more carefully than in previous years.

He suggested that additional medicines could potentially leave smaller markets if international pricing pressures continue to increase.

Why Treatment Choice Matters

Opioid dependence remains a major public health issue in Australia.

Dependence on prescription opioids such as oxycodone and codeine, as well as illicit opioids, can lead to serious medical, psychological, and social consequences. Effective medication-assisted treatment plays a critical role in reducing overdose risk, improving quality of life, and supporting long-term recovery.

Long-acting buprenorphine injections have become an increasingly valuable option because they eliminate the need for daily medication while helping control cravings and withdrawal symptoms.

According to the Australian Institute of Health and Welfare, nearly 58,000 Australians were receiving pharmacotherapy treatment for opioid dependence on a single day in 2025, highlighting the ongoing demand for evidence-based treatment options.

Concerns for Rural and Remote Communities

Pharmacists also worry about the impact on patients living in regional and remote areas.

Because monthly injectable medications require fewer pharmacy visits than daily dosing programs, they have been particularly beneficial for individuals who live long distances from healthcare services.

Pharmacist Angelo Pricolo, who administered Australia's first Buvidal injection in 2020, explained that while both Buvidal and Sublocade contain buprenorphine, patients often respond differently to each formulation.

Some individuals requiring higher doses or longer-lasting symptom control may achieve better outcomes with Sublocade.

Pricolo stressed that maintaining multiple treatment options gives healthcare providers greater flexibility to tailor care to each patient's unique needs.

The Risk of Fewer Treatment Options

Healthcare providers say the issue extends beyond simply replacing one medication with another.

When only one long-acting treatment option remains available, patients become more vulnerable to future supply disruptions, manufacturing shortages, or market withdrawals.

Experts describe addiction treatment as a carefully balanced system where continuity of care is essential. Interruptions in medication access can increase the likelihood of treatment disengagement and may raise the risk of relapse.

For patients who have achieved stability after years of recovery, maintaining uninterrupted access to effective medications is considered a critical component of ongoing care.

Looking Ahead

While Australian health officials work with Indivior to help ensure an orderly transition before Sublocade leaves the market, many clinicians continue to express concern about the long-term impact on patients.

The availability of effective medications remains one of the most important tools in treating opioid dependence and reducing overdose risk. As healthcare systems continue responding to an evolving overdose crisis driven largely by highly potent synthetic opioids such as FYL, addiction specialists emphasize that preserving treatment options is just as important as expanding access.

For many Australians in recovery, having a choice between medications is not simply a matter of convenience—it can be the difference between maintaining stability and facing unnecessary obstacles on the path to long-term recovery.

Source: The Guardian